ProstaLund AB (publ) (PLUN.ST)
SEK 0.22
(-3.86%)
SEK 0.22
(-3.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.57 Million SEK | -52.83% |
| 2022 | -10.67 Million SEK | -41.47% |
| 2021 | -7.54 Million SEK | 22.65% |
| 2020 | -9.74 Million SEK | 4.5% |
| 2019 | -10.2 Million SEK | 18.69% |
| 2018 | -12.55 Million SEK | 22.24% |
| 2017 | -16.14 Million SEK | -58.82% |
| 2016 | -11.22 Million SEK | -14.95% |
| 2015 | -8.84 Million SEK | -20.14% |
| 2014 | -7.29 Million SEK | -72.57% |
| 2013 | -4.18 Million SEK | -70.16% |
| 2012 | 95.99 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.72 Million SEK | -41.07% |
| 2024 Q2 | -7.09 Million SEK | -50.31% |
| 2023 Q3 | -6.24 Million SEK | -53.44% |
| 2023 FY | - SEK | -52.83% |
| 2023 Q1 | -3.17 Million SEK | -1.05% |
| 2023 Q2 | -4.07 Million SEK | -28.19% |
| 2023 Q4 | -3.34 Million SEK | 46.39% |
| 2022 Q2 | -3.62 Million SEK | -69.63% |
| 2022 Q3 | -1.98 Million SEK | 45.19% |
| 2022 Q4 | -3.14 Million SEK | -58.13% |
| 2022 Q1 | -2.13 Million SEK | 4.08% |
| 2022 FY | - SEK | -41.47% |
| 2021 FY | - SEK | 22.65% |
| 2021 Q1 | -1.16 Million SEK | 68.88% |
| 2021 Q3 | -1.69 Million SEK | 38.46% |
| 2021 Q2 | -2.76 Million SEK | -137.81% |
| 2021 Q4 | -2.22 Million SEK | -31.14% |
| 2020 FY | - SEK | 4.5% |
| 2020 Q1 | -1.59 Million SEK | 33.14% |
| 2020 Q2 | -3.11 Million SEK | -95.35% |
| 2020 Q4 | -3.73 Million SEK | -151.08% |
| 2020 Q3 | -1.48 Million SEK | 52.22% |
| 2019 FY | - SEK | 18.69% |
| 2019 Q2 | -3.21 Million SEK | -12.83% |
| 2019 Q1 | -2.84 Million SEK | 16.42% |
| 2019 Q4 | -2.38 Million SEK | -18.93% |
| 2019 Q3 | -2 Million SEK | 37.63% |
| 2018 Q1 | -4.03 Million SEK | 19.03% |
| 2018 Q4 | -3.4 Million SEK | -56.65% |
| 2018 Q3 | -2.17 Million SEK | 34.82% |
| 2018 FY | - SEK | 22.24% |
| 2018 Q2 | -3.33 Million SEK | 17.35% |
| 2017 Q4 | -4.98 Million SEK | -187.98% |
| 2017 FY | - SEK | -58.82% |
| 2017 Q3 | -1.73 Million SEK | 72.58% |
| 2017 Q2 | -6.3 Million SEK | -82.92% |
| 2017 Q1 | -3.44 Million SEK | -19.43% |
| 2016 FY | - SEK | -14.95% |
| 2016 Q3 | -2.09 Million SEK | 21.64% |
| 2016 Q4 | -2.88 Million SEK | -37.72% |
| 2016 Q1 | -3.21 Million SEK | -54.59% |
| 2016 Q2 | -2.67 Million SEK | 16.82% |
| 2015 FY | - SEK | -20.14% |
| 2015 Q4 | -2.08 Million SEK | 24.05% |
| 2015 Q3 | -2.74 Million SEK | 4.63% |
| 2015 Q2 | -2.87 Million SEK | -100.63% |
| 2015 Q1 | -1.43 Million SEK | 19.19% |
| 2014 Q2 | -1.77 Million SEK | -2.72% |
| 2014 Q1 | -1.72 Million SEK | 5.58% |
| 2014 FY | - SEK | -72.57% |
| 2014 Q4 | -1.77 Million SEK | 28.69% |
| 2014 Q3 | -2.48 Million SEK | -40.24% |
| 2013 Q2 | -1.15 Million SEK | -2306.25% |
| 2013 Q1 | -48 Thousand SEK | -115.18% |
| 2013 Q3 | -1.59 Million SEK | -38.1% |
| 2013 Q4 | -1.82 Million SEK | -14.55% |
| 2013 FY | - SEK | -70.16% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q3 | 10.86 Million SEK | 0.0% |
| 2012 Q4 | 316.25 Thousand SEK | -97.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ambea AB (publ) | 2.28 Billion SEK | 100.727% |
| Attendo AB (publ) | 3.11 Billion SEK | 100.532% |
| Humana AB (publ) | 457 Million SEK | 103.626% |